Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis [0.03%]
基于基因型的替卡格雷/普拉格雷与氯吡格雷疗法在携带CYP2C19功能缺失等位基因的卒中患者中的疗效：系统评价和meta分析
Mohitosh Biswas,Murshadul Alam Murad,Maliheh Ershadian et al.
Mohitosh Biswas et al.
Introduction: Transient ischemic attack (TIA) or ischemic stroke (IS) patients may have recurrent stroke incidents, especially when carrying CYP2C19 Loss-of-Function (LoF) alleles and taking clopidogrel. Recent studies su...
Exploring experiential learning opportunities in pharmacogenomics for pharmacy education [0.03%]
药学教育中关于药物基因组学的体验式学习机会探索
Nicole Keuler,Jane McCartney,Renier Coetzee et al.
Nicole Keuler et al.
Introduction: Precision medicine is the future of healthcare, and pharmacists are well-positioned to play a key role in pharmacogenomics (PGx). Experiential learning offers valuable opportunities to gain hands-on experien...
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion [0.03%]
美托洛尔反应的个体差异：细胞色素P450 2D6、药物相互作用和表型转换的影响
Bayan Azizi,David E Lanfear,Jasmine A Luzum
Bayan Azizi
Metoprolol, a β1-selective blocker, is widely used for treating cardiovascular and non-cardiovascular conditions. Its pharmacokinetics (PK) and pharmacodynamics (PD) vary significantly between individuals, in part due to CYP2D6 genetic pol...
Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight [0.03%]
塞普替尼治疗液态活检发现的RET阳性晚期胰腺癌的一例报告
Tarek Assi,Tania Moussa,Cendrella Bou-Orm et al.
Tarek Assi et al.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis and limited effective treatments. Standard chemotherapy offers modest survival benefits, and actionable genetic alterations are rare. RET gene fusions...
Correction [0.03%]
改正的方法
Published Erratum
Pharmacogenomics. 2025 Dec 10:1. DOI:10.1080/14622416.2025.2601450 2025
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis [0.03%]
全外显子组测序识别出与抗结核药物性肝损伤相关的PPIX代谢通路罕见变异
Yu Wu,Lihuan Lu,Fei Wang et al.
Yu Wu et al.
Aims: To screen and validate rare variants in the protoporphyrin IX (PPIX)-metabolizing pathway associated with anti-tuberculosis drug-induced hepatitis (AT-DIH). ...
Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe [0.03%]
津巴布韦胃肠肿瘤患者支持性照护中实施药物基因组学的应用前景与挑战
Tinashe Adrian Mazhindu,Ntokozo Ndlovu,Margaret Z Borok et al.
Tinashe Adrian Mazhindu et al.
Introduction: Supportive care in oncology aims to prevent and manage cancer-related side effects. This study reviews supportive medications for gastrointestinal cancer patients, analyzes usage patterns, biomarker frequenc...
Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes [0.03%]
蒽环类-环磷酰胺-紫杉烷化疗的药物基因组学：CYP多态性和BMI对乳腺癌治疗结果的影响
Tanuma Mistry,Partha Nath,Neyaz Alam et al.
Tanuma Mistry et al.
Aims: Sequential Anthracycline-Taxane chemotherapy is standard treatment for BC. This study examines the combined impact of low BMI and CYP polymorphisms on treatment response. ...
Genetic polymorphisms of VEGFR2 and FGFR2 genes are associated with exposure to sunitinib and cardiovascular toxicity [0.03%]
VEGFR2和FGFR2基因多态性与舒尼替尼暴露及心血管毒性相关性分析
Litaty C Mbatchi,Fanny Leenhardt,Bob-Valéry Occean et al.
Litaty C Mbatchi et al.
Purpose: Sunitinib is a multikinase inhibitor used to treat metastatic renal cell carcinoma (mRCC), with an inter-individual variability of pharmacokinetics and toxicity. Our goal was to assess associations between the ph...